| Literature DB >> 26633970 |
Jin-Shuen Chen1, Chung-Ze Wu2, Nain-Feng Chu3, Li-Chien Chang4, Dee Pei5, Yuh-Feng Lin6.
Abstract
We investigated the role of urokinase plasminogen activator (uPA) and its soluble receptors (suPAR) and plasminogen activator inhibitor-1 (PAI-1) in metabolic syndrome (MetS) components, insulin secretion, and resistance in schoolchildren. We enrolled 387 children, aged 10.3 ± 1.5 years, in Taipei. Anthropometry, fibrinolytic proteins, MetS components, insulin secretion, and resistance were measured. Subjects were divided into normal, overweight, and obese groups. Finally, the relationship between fibrinolytic proteins and metabolic syndrome in boys and girls was analyzed. In boys, PAI-1 was positively associated with body mass index (BMI) percentile, hypertriglyceride, insulin secretion, and resistance. In girls, PAI-1 was positively associated with obesity, hypertriglyceridemia, and insulin secretion. In girls, uPA was positively associated with insulin secretion. suPAR was positively associated with high-sensitivity C-reactive protein in both boys and girls, and with BMI percentile and body fat in girls. The obese boys had higher suPAR and PAI-1 levels than the normal group. The obese girls had higher uPA, suPAR, and PAI-1 than the normal group. Boys and girls with MetS had higher PAI-1. Fibrinolytic proteins, especially PAI-1, are associated with MetS components and insulin secretion in children. Fibrinolytic proteins changes were more likely to occur in girls than in boys.Entities:
Year: 2015 PMID: 26633970 PMCID: PMC4655051 DOI: 10.1155/2015/170987
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Correlation among fibrinolytic proteins, metabolic syndrome components, and HOMA-β and HOMA-IR in boys and girls.
| Boys | Girls | |||||
|---|---|---|---|---|---|---|
| uPA | suPAR | PAI-1 | uPA | suPAR | PAI-1 | |
| Age | 0.091 | −0.120 | 0.092 | −0.020 | −0.151 | 0.137 |
| BMI | −0.065 | 0.072 | 0.189 | 0.084 | 0.174 | 0.118 |
| Body fat | −0.043 | 0.130 | 0.029 | 0.100 | 0.157 | 0.146 |
| FPG | 0.037 | −0.025 | 0.061 | −0.014 | −0.052 | 0.035 |
| SBP | −0.102 | 0.104 | 0.089 | 0.087 | 0.056 | 0.132 |
| DBP | 0.038 | −0.069 | 0.110 | −0.042 | −0.026 | 0.121 |
| TG | −0.027 | 0.059 | 0.194 | −0.010 | −0.080 | 0.164 |
| HDL | 0.109 | −0.116 | −0.148 | 0.089 | −0.068 | −0.099 |
| LDL | 0.049 | −0.075 | 0.128 | 0.031 | −0.034 | 0.020 |
| hsCRP | −0.040 | 0.180 | −0.008 | −0.018 | 0.225 | −0.011 |
| HOMA- | 0.124 | 0.127 | 0.254 | 0.167 | 0.021 | 0.159 |
| HOMA-IR | 0.096 | 0.074 | 0.164 | 0.081 | −0.023 | 0.125 |
uPA: urokinase plasminogen activator, suPAR: soluble urokinase plasminogen activator receptor, PAI-1: plasminogen activator inhibitor-1, BMI: body mass index, FPG: fasting plasma glucose, SBP: systolic blood pressure, DBP: diastolic blood pressure, TG: triglyceride, HDL: high-density lipoprotein-cholesterol, LDL: low-density lipoprotein-cholesterol, HOMA-β (insulin secretion): homeostatic model assessment-β, and HOMA-IR (insulin resistance): homeostatic model assessment-insulin resistance.
<0.05;<0.01.
General characteristics of components of metabolic syndrome, insulin secretion, and resistance in boys and girls.
| Boys | Girls | |||||
|---|---|---|---|---|---|---|
| Normal | Overweight | Obese | Normal | Overweight | Obese | |
|
| 88 | 44 | 40 | 128 | 34 | 27 |
| Age (year) | 10.3 ± 1.6† | 11.1 ± 1.3 | 9.7 ± 1.4† | 10.1 ± 1.5 | 10.5 ± 1.4 | 10.3 ± 1.8 |
| BMI percentile (%) | 53.5 ± 23.8†,§ | 92.3 ± 2.6 | 97.6 ± 1.1 | 48.3 ± 24.1†,§ | 90.1 ± 2.7 | 97.3 ± 1.2 |
| Body fat (%) | 22.2 ± 6.4§ | 23.9 ± 3.3§ | 27.3 ± 2.8 | 19.7 ± 2.8†,§ | 25.0 ± 2.7 | 28.2 ± 1.9 |
| FPG (mmol/L) | 5.07 ± 0.42 | 5.12 ± 0.40 | 5.11 ± 0.43 | 4.93 ± 0.39 | 5.02 ± 0.31 | 4.96 ± 0.36 |
| SBP (mmHg) | 113.0 ± 9.0†,§ | 120.9 ± 9.7 | 122.2 ± 11.3 | 115.8 ± 10.2† | 121.2 ± 9.1 | 120.9 ± 9.5 |
| DBP (mmHg) | 71.2 ± 7.8 | 73.2 ± 8.3 | 72.5 ± 9.4 | 73.8 ± 9.9 | 71.8 ± 6.2 | 75.2 ± 11.2 |
| TG (mg/dL) | 0.62 ± 0.27†,§ | 0.90 ± 0.49 | 0.96 ± 0.57 | 0.73 ± 0.30§ | 0.96 ± 0.38 | 1.31 ± 1.59 |
| HDL (mg/dL) | 1.47 ± 0.33†,§ | 1.29 ± 0.29 | 1.18 ± 0.27 | 1.42 ± 0.29§ | 1.30 ± 0.27 | 1.16 ± 0.33 |
| LDL (mg/dL) | 2.54 ± 0.68 | 2.43 ± 0.57 | 2.64 ± 0.59 | 2.40 ± 0.68 | 2.47 ± 0.50 | 2.64 ± 0.55 |
| hsCRP | 0.68 ± 1.07§ | 0.72 ± 0.84§ | 1.58 ± 1.45 | 0.43 ± 0.82†,§ | 1.03 ± 1.35 | 1.17 ± 1.13 |
| HOMA- | 164.4 ± 164.3§ | 233.1 ± 178.8 | 253.2 ± 118.2 | 209.9 ± 218.4§ | 245.8 ± 214.6 | 362.0 ± 336.5 |
| HOMA-IR | 3.09 ± 3.95 | 4.40 ± 5.90 | 4.10 ± 2.35 | 3.34 ± 4.10§ | 4.24 ± 3.45 | 6.05 ± 5.37 |
| uPA (pg/mL) | 608.6 ± 516.5 | 597.9 ± 468.5 | 614.9 ± 502.8 | 573.8 ± 343.9§ | 511.9 ± 324.5§ | 888.2 ± 899.9 |
| suPAR (pg/mL) | 5509.3 ± 1652.7§ | 5737.3 ± 1449.1 | 6546.0 ± 1679.5 | 5558.0 ± 1604.9§ | 6021.7 ± 1758.6 | 6606.6 ± 2286.0 |
| PAI-1 (ng/mL) | 13.59 ± 8.62§ | 17.88 ± 11.12 | 19.43 ± 14.35 | 16.22 ± 8.73§ | 17.10 ± 9.21 | 21.01 ± 9.83 |
Data shown: mean ± SD, uPA: urokinase plasminogen activator, suPAR: soluble urokinase plasminogen activator receptor, PAI-1: plasminogen activator inhibitor-1, BMI: body mass index, FPG: fasting plasma glucose, SBP: systolic blood pressure, DBP: diastolic blood pressure, TG: triglyceride, HDL: high-density lipoprotein-cholesterol, LDL: low-density lipoprotein-cholesterol, HOMA-β (insulin secretion): homeostatic model assessment-β, and HOMA-IR (insulin resistance): homeostatic model assessment-insulin resistance; P < 0.05 against normal, † P < 0.05 against overweight, and § P < 0.05 against obese.
Figure 1(a) Urokinase plasminogen activator (uPA), (b) soluble urokinase plasminogen activator receptor (suPAR), and (c) plasminogen activator inhibitor-1 (PAI-1) in normal, overweight, and obese children. The uPA levels in obese girls are higher than in overweight and normal girls. In addition, suPAR and PAI-1 levels in the obese children are higher than in the normal group in both genders. Mean ± SE; P < 0.05.
Figure 2(a) Urokinase plasminogen activator (uPA), (b) soluble urokinase plasminogen activator receptor (suPAR), and (c) plasminogen activator inhibitor-1 (PAI-1) in children with and without metabolic syndrome (MetS). The uPA and suPAR levels are not significantly different between children with and without MetS. However, children with MetS have higher PAI-1 levels. Mean ± SE; P < 0.05.